Literature DB >> 15580564

Molecular and functional analysis of intragenic SMN1 mutations in patients with spinal muscular atrophy.

Y Sun1, M Grimmler, V Schwarzer, F Schoenen, U Fischer, B Wirth.   

Abstract

The autosomal recessive spinal muscular atrophy (SMA), a neuromuscular disease and frequent cause of early death in childhood, is caused in 96% of patients by homozygous absence of the survival motor neuron gene (SMN1). The severity of the disease is mainly determined by the copy number of SMN2, a copy gene which predominantly produces exon 7-skipped transcripts and only low amount of full-length transcripts that encode for a protein identical to SMN1. Only about 4% of SMA patients bear one SMN1 copy with an intragenic mutation. A comprehensive molecular genetic analysis of 34 SMA patients who carry one SMN1 gene is presented, including 18 that were previously published. Haplotype analysis with the microsatellite markers Ag1-CA and C212 in these SMA families turned out to be a reliable accessory method in predicting known SMN1 mutations in SMA patients carrying one SMN1 copy. Five novel missense mutations were identified that are localized in: exon 2a c.88G>A (p.D30N) and c.131A>T (p.D44V); exon 3 c.283G>C (p.G95R) and c.332C>G (p.A111G); and exon 6 c.784A>G (p.S262G), respectively. The survival motor neuron (SMN) protein has been shown to be a component of a large complex (termed the SMN complex) that promotes the formation of spliceosomal U small nuclear ribonucleoproteins (snRNPs). Within this complex, SMN forms oligomers and directly interacts via its N-terminus with SMN-interacting protein 1 (SIP1) and via its central Tudor domain with spliceosomal (Sm) proteins. We performed in vitro interaction studies to test whether SMA-causing missense mutations identified in this study interfere with the reported interactions of SMN. Our results show that mutations p.G95R and p.A111G reduce SMN binding to Sm proteins, further confirming the previous finding that the Tudor domain is the essential binding site of SMN to Sm-proteins. However, all mutations, including those in exon 2a, a region shown to be important for the binding of SMN to SIP1, do not disturb the interaction of SMN to SIP1. (c) 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15580564     DOI: 10.1002/humu.20111

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  40 in total

Review 1.  Spinal muscular atrophy: new and emerging insights from model mice.

Authors:  Gyu-Hwan Park; Shingo Kariya; Umrao R Monani
Journal:  Curr Neurol Neurosci Rep       Date:  2010-03       Impact factor: 5.081

2.  Gemin proteins are required for efficient assembly of Sm-class ribonucleoproteins.

Authors:  Karl B Shpargel; A Gregory Matera
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-21       Impact factor: 11.205

Review 3.  Spliceosomal small nuclear ribonucleoprotein biogenesis defects and motor neuron selectivity in spinal muscular atrophy.

Authors:  Eileen Workman; Stephen J Kolb; Daniel J Battle
Journal:  Brain Res       Date:  2012-02-28       Impact factor: 3.252

4.  A Drosophila model of spinal muscular atrophy uncouples snRNP biogenesis functions of survival motor neuron from locomotion and viability defects.

Authors:  Kavita Praveen; Ying Wen; A Gregory Matera
Journal:  Cell Rep       Date:  2012-06-21       Impact factor: 9.423

Review 5.  Advances in therapeutic development for spinal muscular atrophy.

Authors:  Matthew D Howell; Natalia N Singh; Ravindra N Singh
Journal:  Future Med Chem       Date:  2014-06       Impact factor: 3.808

6.  A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse.

Authors:  Paul N Porensky; Chalermchai Mitrpant; Vicki L McGovern; Adam K Bevan; Kevin D Foust; Brain K Kaspar; Stephen D Wilton; Arthur H M Burghes
Journal:  Hum Mol Genet       Date:  2011-12-20       Impact factor: 6.150

7.  Neurocalcin Delta Suppression Protects against Spinal Muscular Atrophy in Humans and across Species by Restoring Impaired Endocytosis.

Authors:  Markus Riessland; Anna Kaczmarek; Svenja Schneider; Kathryn J Swoboda; Heiko Löhr; Cathleen Bradler; Vanessa Grysko; Maria Dimitriadi; Seyyedmohsen Hosseinibarkooie; Laura Torres-Benito; Miriam Peters; Aaradhita Upadhyay; Nasim Biglari; Sandra Kröber; Irmgard Hölker; Lutz Garbes; Christian Gilissen; Alexander Hoischen; Gudrun Nürnberg; Peter Nürnberg; Michael Walter; Frank Rigo; C Frank Bennett; Min Jeong Kye; Anne C Hart; Matthias Hammerschmidt; Peter Kloppenburg; Brunhilde Wirth
Journal:  Am J Hum Genet       Date:  2017-01-26       Impact factor: 11.025

8.  Intragenic complementation of amino and carboxy terminal SMN missense mutations can rescue Smn null mice.

Authors:  Vicki L McGovern; Kaitlyn M Kray; W David Arnold; Sandra I Duque; Chitra C Iyer; Aurélie Massoni-Laporte; Eileen Workman; Aalapi Patel; Daniel J Battle; Arthur H M Burghes
Journal:  Hum Mol Genet       Date:  2020-11-01       Impact factor: 6.150

9.  Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene.

Authors:  Laura Alías; Sara Bernal; Pablo Fuentes-Prior; María Jesus Barceló; Eva Also; Rebeca Martínez-Hernández; Francisco J Rodríguez-Alvarez; Yolanda Martín; Elena Aller; Elena Grau; Ana Peciña; Guillermo Antiñolo; Enrique Galán; Alberto L Rosa; Miguel Fernández-Burriel; Salud Borrego; José M Millán; Concepción Hernández-Chico; Montserrat Baiget; Eduardo F Tizzano
Journal:  Hum Genet       Date:  2008-12-03       Impact factor: 4.132

Review 10.  SMN regulation in SMA and in response to stress: new paradigms and therapeutic possibilities.

Authors:  Catherine E Dominguez; David Cunningham; Dawn S Chandler
Journal:  Hum Genet       Date:  2017-08-29       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.